Clinical trials: Graft-vs-host Disease
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Pain, Healthy
Predicting Central Pain Among People With a Spinal Cord Injury by Evaluating Mechanisms Regulating Pain and Efficacy Testing of the TENS Apparatus
People with a Spinal Cord Injury can develop chronic pain within months of the injury. Up to 80% of the patients will develop chronic pain called "central pain" and describe the pain as: burning, stabbing, or "like electricity."…
- Trial name
- NCT01726881
- Testing
- Thermal stimulation, Mechanical stimulation, Transcutaneous Electrical Nerve Stimulator (TENS)
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
GVHD, Chronic
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2.
- Trial name
- NCT06169722
- Testing
- TDI01 suspension
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Migraine Disorders
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.
- Trial name
- NCT03716505
- Testing
- gammaCore Sapphire active
- Where
- 30 sites in United States
- Volunteers
- 231 people
- Sponsor
- ElectroCore INC
Graft Versus Host Disease, Leukemia
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00005988
- Testing
- cyclophosphamide, cyclosporine, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL)
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant.
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome)
- Trial name
- ACCELERATE (NCT06859424)
- Testing
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C
- Where
- 13 sites in United States
- Volunteers
- 358 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Stroke, Chronic
Effects of Dualsite Anodic tDCS on Lower Limbs Function in Patients After Stroke: Randomized, Double-blind, Placebo-controlled, Crossover Trial
It is currently known that Transcranial Direct Current Stimulation (tDCS) can modulate cortical activity, being considered an important resource in the treatment of sequelae resulting from stroke.
- Trial name
- NCT04850963
- Testing
- Transcranial direct current stimulation (Anodal tDCS) + dual-task training, Transcranial direct current stimulation (tDCS dualsite) + dual-task traning
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Federal University of Paraíba
Stroke
Brain State-dependent PCMS in Chronic Stroke
After stroke, people often have difficulty using their hands. Combined brain and nerve stimulation can strengthen the neural pathways that control hand function.
- Trial name
- NCT04830163
- Testing
- Brain state-dependent paired corticomotoneuronal stimulation (PCMS)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Texas at Austin
Myelofibrosis
Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France
The investigators would like to conduct a retrospective study in five centers in France in the goal to evaluate the survival of patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis.
- Trial name
- SYMFASCT (NCT04282421)
- Volunteers
- 58 people
- Sponsor
- Central Hospital, Nancy, France
Chronic Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
This phase I trial studies the side effects of leflunomide in treating patients with steroid dependent chronic graft versus host disease (cGVHD). cGVHD is a common complication of bone marrow transplant.
- Trial name
- NCT04212416
- Testing
- Leflunomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Gingivitis; Chronic, Oxidative Stress
Efficacy of Green and White Tea Extract Mouthwashes in the Management of Plaque-induced Gingivitis: A Clinical and Biochemical Study
Background and objective: Tea is the second most consumed drink in the world after water. Gingivitis is among the most common infectious diseases.
- Conditions
- Gingivitis; Chronic, Oxidative Stress, Inflammation
- Trial name
- NCT05861206
- Testing
- GT-MW group (5% Green tea), WT-MW group (5% White tea),EO-MW group (Listerine mouthrinse), CHX-MW group (0.12% CHX, as a positive control group)
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Yağmur Saraç Gül
Acute GVH Disease
MTX and Steroid for aGVHD Treatment
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT04677868
- Testing
- Methotrexate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Chronic Graft Versus Host Disease
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment.
- Trial name
- NCT02337517
- Testing
- Laboratory Biomarker Analysis, Vismodegib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Acute Graft-versus-host Disease
A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)
The primary purpose of the study is to assess the safety and pharmacokinetics (PK) of GDC-8264 in participants with acute graft-versus-host disease (aGVHD).
- Trial name
- NCT05673876
- Testing
- GDC-8264
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Genentech, Inc.
Chronic Ocular Graft-versus-host Disease
Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
- Trial name
- NCT03990051
- Testing
- Pro-ocular™ topical gel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Glia, LLC
Graft-versus-host Disease, Relapse
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant (BMT) for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis and treatment.
- Trial name
- NCT01941394
- Testing
- Mesenchymal stem cells
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- National Research Center for Hematology, Russia
Steroid-Refractory Chronic GVHD
Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Chronic GVHD is the most common late complication following allogeneic stem cell transplantation. It has features resembling autoimmune disorders such as scleroderma, primary biliary cirrhosis, bronchiolitis obliterans, chronic…
- Trial name
- NCT00472225
- Testing
- Rituximab
- Where
- 9 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- The Korean Society of Hematopoietic Stem Cell Transplantation
Sclerotic Graft Versus Host Disease, Imatinib Mesylate
Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
Background: Chronic graft-versus-host disease (GVHD) is a common complication of stem cell transplant, resulting from the donor's immune cells attacking the cells of the body of the recipient.
- Trial name
- NCT00702689
- Testing
- Gleevec, STI571(Imatinib Mesylate)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Graft-Versus-Host Disease
Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)
A trial to assess safety of four doses of MEDI 507 combined with another drug for initial treatment of at least Grade II acute Graft-vs-Host Disease in recipients.
- Trial name
- NCT00806208
- Testing
- MEDI-507
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.